Clinical Developments in Renal Cell Carcinoma

EP. 1: Introduction and Review of the COMPARZ Trial in RCC

July 1st 2013

EP. 2: COMPARZ Trial and Alternate Sunitinib Dosing Schedule

July 1st 2013

EP. 3: PISCES Trial and Patient Treatment Preference in mRCC

July 1st 2013

EP. 4: AGILE Trial: Frontline Axitinib Versus Sorafenib in mRCC

July 1st 2013

EP. 5: Utilizing Frontline Bevacizumab in mRCC

July 1st 2013

EP. 6: Frontline Sunitinib Compared to Everolimus in mRCC

July 1st 2013

EP. 7: AXIS Trial: Second-Line Axitinib Versus Sorafenib

July 1st 2013

EP. 8: Determining Progression in Renal Cell Carcinoma

July 1st 2013

EP. 9: INTORSECT Trial: Second-Line Temsirolimus Versus Sorafenib

July 1st 2013

EP. 10: Novel Agents in Development for Renal Cell Carcinoma

July 1st 2013

EP. 11: Immune Checkpoint Inhibition in Renal Cell Carcinoma

July 1st 2013

EP. 12: Unmet Needs in Renal Cell Carcinoma

July 1st 2013

EP. 13: Conclusion: Key Take-Away Points and Cardiac Safety

July 1st 2013